Therefore, a comprehensive understanding of the mechanism of PRAT-derived chemerin modulation of the lipid metabolism in cancer and tumor-associated macrophage activity may offer new perspectives for RCC therapy. Here, RARRES2 is linked to renal cell carcinoma.